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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that selectively affects the
motor neurons. The details of the mechanisms of selective motor-neuron death remain unknown and no effective
therapy has been developed. We investigated the therapy with bone-marrow mononuclear cells (BMMC) in a mouse
model of ALS (SOD1G93A mice).
Methods: We injected 106 BMMC into the lumbar portion of the spinal cord of SOD1G93A mice in presymptomatic
(9 weeks old) and symptomatic (14 weeks old) phases. In each condition, we analyzed the progression of disease and
the lifespan of the animals.
Results: We observed a mild transitory delay in the disease progression in the animals injected with BMMC in the
presymptomatic phase. However, we observed no increase in the lifespan. When we injected BMMC in the symptomatic
phase, we observed no difference in the animals’ lifespan or in the disease progression. Immunohistochemistry for NeuN
showed a decrease in the number of motor neurons during the course of the disease, and this decrease was not affected
by either treatment. Using different strategies to track the BMMC, we noted that few cells remained in the spinal
cord after transplantation. This observation could explain why the BMMC therapy had only a transitory effect.
Conclusion: This is the first report of intraspinal BMMC therapy in a mouse model of ALS. We conclude this
cellular therapy has only a mild transitory effect when performed in the presymptomatic phase of the disease.
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Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disease involving the death of motor neurons in
the spinal cord, brain stem, and motor cortex. Approxi-
mately 90 % of ALS cases are sporadic, and the remaining
10 % are inherited (familial). A mutation in the Cu/Zn
superoxide dismutase 1 (SOD1) gene is responsible for
20 % of the familial forms [1]. In rodents, overexpression
of the human SOD1 mutant protein leads to progressive
motor-neuron degeneration, which mimics the patho-
logical progression observed in humans [2, 3].
Several lines of evidence suggest that nonneuronal
cells play an important role in ALS pathogenesis, since
both the astrocytes and the microglia expressing the mu-
tated SOD1 are toxic to motor neurons and contribute
significantly to the disease progression [4–8]. In
addition, immune cells such as T lymphocytes have also
been implicated in ALS, and an increase in the number
of these cells in the affected areas of the central nervous
system (CNS) has been described both in humans and in
mouse models [9–11]. The CNS-infiltrating CD4 T lym-
phocytes seem to communicate with the microglia, and
this dialog directs the microglia to a neuroprotective
profile [12, 13].
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Currently, the only treatment for ALS is Riluzole®,
Sanofi S.A., (Gentilly, Paris, France), which increases the
patient’s lifespan by only 3 months [14]. Alternatively,
cell therapies with different types of stem cells have been
suggested as a possible therapeutic approach. Bone
marrow-derived stem cells have been used in several
models of neurological disease, including ALS [15–19].
In several of these studies, beneficial effects were ob-
served; the suggested mechanism of action includes re-
lease of trophic factors and local or systemic modulation
of the immune response.
In addition to different cell types, different routes of in-
jection have been tested in animal ALS models; for in-
stance, intravenous, intrathecal, intramuscular, and direct
delivery in the spinal cord [16, 20–22]. In the majority of
studies using animal ALS models, the cells were injected
in the presymptomatic phase of the disease. For clinical
translation, however, cell therapy during the symptomatic
phase could be more meaningful. In this respect, a few
clinical trials with bone marrow mononuclear cells or
mesenchymal stem cells in ALS patients showed that
these therapies are safe, although the efficacy of these
therapies still needs to be investigated [23, 24].
In this study, we investigated the potential therapeutic
benefit of bone marrow-derived mononuclear cells
(BMMC) injected directly into the lumbar spinal cord of
ALS mice in the presymptomatic or symptomatic phases.
BMMC have been broadly tested in preclinical models of
traumas or neurodegenerative diseases in the nervous sys-
tem, showing positive results. These cells are easy to
isolate and require minimum manipulation prior to trans-
plant, becoming a good candidate for cell therapies. Using
different models of neurological diseases, our group
showed in previous publications that BMMC transplant-
ation results in neuronal protection, axonal regeneration,
decreases microglia activation, and improves functional
recovery [17, 25, 26]. More importantly, this is the first
study using this approach, and we report here that the
BMMC therapy delayed the animals’ functional outcome
only when administered in the presymptomatic phase.
Methods
Animals
All of the experiments were conducted in accordance with
the recommendations of the National Institutes of Health
Guide for the Care and Use of Laboratory Animals, and
were approved by the Committee for the Use of Experi-
mental Animals of our institution (permit number:
IBCCF213-09/16). The strain of mice used was B6SJL-
Tg(SOD1-G93A)1Gur (SOD1G93A), developed by Gurney
in 1994 [2], which carries the mutant allele human SOD1
containing the Gly 93→Ala substitution. The colony was
maintained by crossing transgenic male founders with wild-
type female mice. The number of human SOD1 transgenic
copies was assessed as described in the Jackson Laboratory
manual (https://www.jax.org/strain/002726#jump-nav-5).
The breeding pairs were donated by the ALS Foundation
through Dr R Brown (University of Massachusetts, Wor-
cester, USA).
Isolation and labeling of mononuclear bone marrow cells
Bone marrow was obtained from the femur and tibia of
adult B6SJL mice of both genders. BMMC were isolated
by density gradient (Histopaque 1083; Sigma, St. Louis,
MO, USA) and washed three times with phosphate-
buffered saline (PBS). Cells were suspended in saline
(250,000 cells/μl) and injected into the lumbar portion
of the spinal cord as described in the next section.
In some animals the BMMC were labeled, before trans-
plantation, with a fluorescent marker (CellTrace™ Far Red
DDAO-SE; Life Technologies, Carlsbad, CA, USA) or with
iron nanoparticles (superparamagnetic iron nanoparticles
(SPION), FeraTrack™; Miltenyi Biotec, Bergisch Gladbach,
Germany). For the fluorescent labeling, BMMC were incu-
bated with Cell Trace™ (1:1000) diluted in Dulbecco’s
modified Eagle’s medium (DMEM)–F12 (Life Technolo-
gies) for 40 minutes at 37 ° C, washed five times with PBS,
and then suspended in saline.
For the SPION labeling, BMMC were incubated with
FeraTrack™ contrast particles and FeraTrack™ loading re-
agent for 3 hours at 37 °C/5 % CO2, as described previ-
ously by Zaverucha-do-Valle et al. [27]. After incubation,
the cells were washed three times with PBS and sus-
pended in saline. The labeled cells were injected in week
9 or week 14. Cells were tracked in vivo by magnetic res-
onance imaging (MRI) measurements at 1 and 7 days
after the injection and in the end stage of the disease.
Images were acquired with a 7 T magnetic resonance
scanner (7 T/400 horizontal Varian scanner; Agilent Tech-
nologies, Santa Clara, CA, USA). Four proton-density fast
spin-echo imaging sequences (repetition time = 2000 mil-
liseconds; echo spacing = 10.5–12 milliseconds: matrix =
192 × 192; slice thickness = 0.5 mm; 7–10 continuous
slices, no gap; 16 averages, axial field of view (FOV) =
25 mm× 25 mm, coronal FOV = 30 mm× 30 mm, sagittal
FOV = 40 mm× 30 mm, total sagittal FOV = 50 mm×
30 mm) were used to investigate the spinal cord region.
Prior to image analysis, datasets were anonymized. For
each dataset, all images were visually inspected for im-
portant artifacts. Data were processed using MRIcron
software (Columbia, SC, USA).
Injection
SOD1G93A animals were injected with BMMC or vehicle
(saline) at 9 or 14 weeks old. Mice were anesthetized with
xylazine (15 mg/kg; Vetbrands and ketamine (150 mg/kg;
Vetbrands) (Goiânia, GO, Brazil) intraperitoneally. The ani-
mals were immobilized and the spine was exposed. The
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vertebrae were carefully separated using two fine tweezers in
order to reveal the lumbar spinal cord (L4–L5). The BMMC
(106 cells) or saline were injected intraparenchymally with a
glass micropipette connected to the nanoinjector (Nanoin-
ject II; Drummond Scientific Company, Broomall, PA, USA)
at the rate of 1 μl/minute for a total volume of 4 μl. After re-
covery from anesthesia, the animals from both groups were
returned to the animal facility and kept in cages with food
and water ad libitum. To assess the survival and functional
outcome, the animals were divided into five groups: BMMC
treated in week 9 (n= 22), saline injected in week 9 (n= 24),
BMMC treated in week 14 (n = 22), saline injected in week
14 (n= 22), and wild-type (n = 16). Equal numbers of male
and female were used in each group.
Functional evaluation
Functional tests were performed weekly in all experi-
mental groups by blinded investigators. The tests per-
formed were the rotarod, hanging wire, and motor score.
In the rotarod test, the animals were placed in a rolling
rod (maximum of 180 seconds) with an accelerating
speed from 20 to 35 rpm. In the hanging-wire test, the
animals were placed on the wire lid from their housing
cage, where they remained upside down until they fell
(maximum time 90 seconds). The longest period that
the animal remained in the rotarod test and hanging-
wire test was recorded after three trials.
In the motor score, the animals were graded as fol-
lows: 4 = no sign of motor dysfunction, 3 = hind-limb
tremors when suspended by the tail and collapse or par-
tial collapse of leg extension, 2 = evident motor dysfunc-
tion, 1 = paralysis in at least one limb, and 0 = not able
to right itself within 30 seconds when placed on its side.
The statistical analyses were performed with the two-
way analysis of variance (ANOVA) and Bonferroni post-
test in GraphPad Prism 4.02 (GraphPad Software, Inc.,
La Jolla, CA, USA). For survival comparison, the log-
rank test was used. Statistical significance was consid-
ered when p ≤0.05. All data are presented as mean ±
standard error of the mean (SEM).
Tissue preparation and immunohistochemistry
Animals (n = 5/6 animals per group) were perfused
through the heart with ice-cold saline, followed by a so-
lution of 4 % paraformaldehyde in 0.1 M phosphate buf-
fer, pH 7.4, via the ascending aorta. The spinal cords
were then removed, and cryoprotected by immersion in
20 % sucrose followed by 30 % sucrose in phosphate buf-
fer. The spinal cords were sectioned transversely at 20 μm
on a cryostat (CM 1850; Leica, Wetzlar, Germany) and
collected on gelatin-coated slides.
For immunohistochemistry, sections were washed
three times with PBS with 0.3 % Triton X-100, incubated
with 5 % normal goat serum (NGS; Sigma) in PBS for
30 minutes, and then incubated with the primary anti-
bodies monoclonal mouse anti-NeuN (1:200, #MAB 377;
Chemicon, Temecula, CA, USA) and polyclonal rabbit
anti-Iba1 (1:400, #019-19741; Wako, Richmond, VA,
USA) overnight at 4 °C. After the primary incubations,
the appropriate secondary Cy3®-conjugated or Alexa®
488-conjugated antibodies (Jackson ImmunoResearch,
West Grove, PA, USA and Invitrogen Inc., Carlsbad,
CA, respectively) were used. In some cases, the sections
were incubated with TO-PRO®-3 (1:1000; Invitrogen) for
nuclei staining. Sections were mounted with VectaShield®
(Vector, Burlingame, CA, USA) and analyzed using con-
focal microscopes (LSM 510 META or LSM 510 META
NLO; Zeiss GmbH, Oberkochen, Germany).
Motor-neuron and microglia quantification
For motor-neuron quantification we stained the lumbar
spinal cord with NeuN antibody. We inspected every
fifth transverse section of a total of 10 sections from the
anterior horn of the lumbar spinal cord (20 μm). Counts
were made using a 20× objective on a Zeiss Axiovert
200 M microscope equipped with fluorescence optics.
The size of NeuN-positive cells in the anterior horn was
quantified; cells featuring cell bodies with cross-sectional
area ≥250 μm2 were considered motor neurons. Smaller
NeuN-positive cells were considered interneurons.
For microglia quantification, we stained the spinal
cord with Iba1 antibody. We quantified every fifth sec-
tion of a total of 20 transverse sections from the anterior
horn of the lumbar spinal cord (20 μm). Counts were
made using a 40× objective on a Zeiss Axiovert 200 M
microscope with fluorescence optics.
Statistical analysis was performed by one-way ANOVA
and Tukey’s multiple comparison test in GraphPad Prism
4.02 (GraphPad Software, Inc., La Jolla, CA, USA). Statis-
tical significance was considered when p ≤0.05. All data
are presented as mean ± SEM.
Results
Effect of BMMC treatment on motor functional outcome
To assess the effect of BMMC transplanted directly into
the lumbar spinal cord, we analyzed the disease func-
tional outcome using the rotarod, hanging-wire, and
motor-score tests. We divided the animals into two
groups: presymptomatic animals, which were injected
with saline (n = 24) or BMMC (n = 22) in week 9; and
symptomatic animals, which received the injection only
in week 14 (saline, n = 22; BMMC, n = 22). These groups
were also compared with wild-type animals of equivalent
ages (n = 16).
In the rotarod test, compared with the wild-type mice,
the animals treated with BMMC in the presymptomatic
phase started to show motor deficits in week 13, while
in the untreated group this decline was already apparent
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in week 11 (Fig. 1a). In the hanging-wire test, we also
observed that the saline group started to show loss of
function 2 weeks before the treated group (Fig. 1c). In
the motor score analyses, we observed a delay in the
functional loss in the BMMC-treated animals in week 9
(Fig. 1e). This group showed deficits in week 15 com-
pared with wild-type mice, while saline injected animals
showed a deficit already in week 14. However, we did
not observe differences between the BMMC-injected
and saline-injected animals.
Fig. 1 Functional outcome and survival of SOD-1G93A mice after BMMC therapy. a, b Rotarod test, c, d hanging-wire test, e, f motor-score test, and g, h
cumulative survival. SOD-1G93A mice were injected with BMMCs or saline at two different time points: presymptomatic phase (9 weeks old a, c, e, g) and
symptomatic phase (14 weeks old b, d, f, h). The animals that received the treatment in week 9 showed a 2-week delay in the functional loss in the
rotarod and hanging-wire tests. In the motor-score analyses, the saline-injected animals in week 9 showed a decline in week 14, while the BMMC-treated
animals showed a decline in week 15. No differences were observed between the saline-injected and BMMC-injected animals in week 9 in the cumulative
survival. The therapy in week 14 did not show an effect in any analysis performed. Arrows indicate week of treatment. *WT vs. saline (p <0.05), #WT vs.
BMMC (p <0.05). BMMC bone marrow-derived mononuclear cells, SOD1 Cu/Zn superoxide dismutase 1, WT wild-type
Gubert et al. Stem Cell Research & Therapy  (2016) 7:41 Page 4 of 14
The animals treated with BMMCs in the symptomatic
phase showed motor deficit as early as at the injection day
when measured by all functional tests; and these deficits
were never recovered or stabilized (Fig. 1b, d, f ).
To determine whether the treatment could affect differ-
ently males and females, we performed a new analysis by
gender. In the presymptomatic animals, we could observe
that female mice treated with BMMC showed a better per-
formance in all tests described than the saline-injected fe-
male mice, when we compared both of them with the
wild-type group (Fig. 2b, d, f ). Male animals treated in
week 9 showed a difference only in the hanging-wire test,
where we could observe a delay in the functional loss
(Fig. 2c). In the symptomatic animals, we observed a
Fig. 2 Gender effect in the functional outcome of SOD-1G93A mice after BMMC therapy. a, b, g Rotarod test, c, d hanging-wire test, and e, f, h
motor-score test. Female SOD-1G93A animals that received the treatment in week 9 showed a delay in the functional loss in all tests performed b,
d, f. Male animals treated in week 9 showed a delay only in the hanging-wire test c. The therapy in week 14 improved the rotarod performance
in males g and delayed the deficit analyzed by motor score grade in BMMC-injected females h. Arrows indicate week of treatment. *WT vs. saline
(p <0.05), #WT vs. BMMC (p <0.05). BMMC bone marrow-derived mononuclear cells, WT wild-type
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difference in the treated male animals only for the rotarod
test (Fig. 2g). In this test, we observed that 1 week after
treatment the animals improved their performance (week
15; Fig. 2g). However, this effect was not sustained in the
following weeks. Moreover, when we compared both
female groups with wild-type females we observed a 1-
week delay in the manifestation of motor-score deficits
in the BMMC animals when compared with the saline
group (Fig. 2h).
There were no differences in survival between the
BMMC-treated animals in the presymptomatic phase or
the BMMC-treated animals in the symptomatic phase
compared with the untreated controls (BMMC presymp-
tomatic: 127.86 ± 7.05 days, saline presymptomatic:
130.33 ± 9.12 days, p = 0.303; BMMC postsymptomatic:
137.27 ± 13 days, saline postsymptomatic: 132.45 ±
9.323 days, p = 0.11) (Fig. 1g, h). However, we observed
an increase in survival of BMMC-treated animals, in
week 14, compared with noninjected mice (SOD1 non-
injected: 129.54 ± 10.4; n = 64; male:female = 1:1; p <0.05)
(Fig. 1h). Also, it is important to notice that only
BMMC-treated animals in the symptomatic phase (two
of a total of 22; male:female = 1:1) survived longer than
160 days. We did not observe any gender effect in the
survival in animals treated in week 9 (male BMMC pre-
symptomatic: 125.90 ± 7.84 days, male saline presymp-
tomatic: 130.46 ± 7.81 days, p = 0.06; female BMMC
presymptomatic: 130.07 ± 6.43 days, female saline pre-
symptomatic: 130 ± 10.38 days, p = 0.92). We also did
not observe a difference by gender in the animals treated
in week 14 (male BMMC postsymptomatic: 134.45 ±
14.55 days, male saline postsymptomatic: 129 ± 9.90 days,
p = 0.35; female BMMC postsymptomatic: 138.53 ±
10.98 days, female saline postsymptomatic: 134.58 ±
8.4 days, p = 0.33).
Neuronal survival and microglia activation
To determine whether the BMMC injection could have
any local effect on the spinal cord, we analyzed the neur-
onal survival and microglia activation in the anterior
horn of the lumbar spinal cord. Neuronal survival was
analyzed using NeuN staining, and motor neurons were
distinguished from interneurons by size (see Materials
and methods; Fig. 3). We analyzed the spinal cord of the
animals injected in the presymptomatic phase in week
12, 3 weeks after the injection. At this age we could
already observe a significant decrease in the number of
motor neurons in the lumbar spinal cord compared with
Fig. 3 Quantification of motor neurons in the anterior horn of the spinal cord. The number of NeuN-positive cells was quantified in week 12 in
the presymptomatic injected animals a and in week 15 in the symptomatic injected animals b. Both saline-injected and BMMC-injected mice
showed a decrease in the number of motor neurons compared with the wild-type mice at the time point analyzed. There was no difference in
the number of motor neurons after the treatment with BMMC injected in week 9 or in week 14 c–e. Representative images of NeuN expression
in wild-type mice c, saline-injected animals in week 9 d, and BMMC-injected animals in week 9 e. *p <0.01. Scale bar: 50 μm. BMMC bone
marrow-derived mononuclear cells, WT wild-type
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the wild-type animals. These data are consistent with
the motor-function analyses, which showed a decline in
the untreated animals in week 12. The BMMC treatment
in the presymptomatic phase did not affect the motor-
neuron survival (saline injected in week 9: 79.02 ± 11.3
cells/mm2, n = 6; BMMC injected in week 9: 76.05 ±
17.54 cells/mm2, n = 5; wild-type: 105.8 ± 19.75 cells/
mm2, n = 4) (Fig. 3a).
In the symptomatic treatment protocol, we analyzed the
spinal cord in week 15, 1 week after the BMMC or saline
injection. As expected, we observed a significant reduction
in the number of motor neurons in the untreated animals
compared with the wild-type; however, the treatment did
not prevent this loss (saline injected in week 14: 66.3 ±
14.69 cells/mm2, n = 7; BMMC injected in week 14: 66.96
± 23.04 cells/mm2, n = 8) (Fig. 3b). Importantly, the num-
ber of interneurons observed in the anterior horn did not
change in the transgenic animals compared with the wild-
type animals at the time points analyzed (saline injected in
week 9: 132.8 ± 74.64 cells/mm2, n = 6; BMMC injected in
week 9: 167.3 ± 87.53 cells/mm2, n = 6; saline injected in
week 14: 159.3 ± 73.61 cells/mm2, n = 8; BMMC injected in
week 14: 142.2 ± 41.99 cells/mm2, n = 8; wild-type: 168.6 ±
102.7 cells/mm2, n = 7) (Additional file 1: Figure S1). At
the end stage of the disease, we observed a more extensive
loss of motor neurons in the anterior horn. In this case we
also did not observe any preservation of motor neurons
after the BMMC injection, in either the presymptomatic or
symptomatic phase (saline injected in week 9: 24.03 ± 6.33
cells/mm2, n = 4; BMMC injected in week 9: 25.63 ± 14.9
cells/mm2, n = 4; saline injected in week 14: 26.88 ± 10.92
cells/mm2, n = 5; BMMC injected in week 14: 14.68 ± 11.66
cells/mm2, n = 5) (Additional file 1: Figure S1).
Microglia cells in the anterior horn were stained with
Iba1. In the presymptomatic treated animals, we ob-
served an increase in the number of microglia in week
12 in the untreated compared with the wild-type animals
(Fig. 4). The BMMC animals treated in the presymptom-
atic phase showed a similar increase (saline injected in
week 9: 539.6 ± 149.1 cells/mm2, n = 7; BMMC injected
in week 9: 495.5 ± 126.5 cells/mm2, n = 6; wild-type:
172.2 ± 116.7 cells/mm2, n = 6) (Fig. 4d).
The animals treated in the symptomatic phase showed a
similar pattern as the presymptomatic groups: both saline
and BMMC groups, at 15 weeks of age, had an increased
number of microglia in the lumbar anterior horn com-
pared with the wild-type animals (saline injected in week
14: 705.0 ± 190.0 cells/mm2, n = 8; BMMC injected in
week 14: 861.3 ± 166.1 cells/mm2, n = 8) (Fig. 4g). How-
ever, we did not observe a difference between the treated
and untreated groups.
At the end stage of the disease, the number of microglia
increased greatly compared with the wild-type animals;
however, there was no difference between the untreated
animals and the BMMC-injected animals in the presymp-
tomatic or symptomatic phase (saline injected in week 9:
877.56 ± 160.8 cells/mm2, n = 4; BMMC injected in week
9: 1016.36 ± 147.1 cells/mm2, n = 5; saline injected in week
Fig. 4 Quantification of microglial cells in the anterior horn of the spinal cord. The number of Iba1-positive cells was quantified in week 12 in the
presymptomatic injected animals b–d and in week 15 in the symptomatic injected animals e–g. Iba1-positive cells in the wild-type animals are
shown in a. The saline-injected and BMMC-injected mice showed an increase in the number of Iba1-positive cells compared with the wild-type
mice. There was no difference in the number of microglia cells after the treatment with BMMC injected in week 9 or week 14. *p <0.01, **p <0.001.
Scale bar: 50 μm. BMMC bone marrow-derived mononuclear cells, SOD1 Cu/Zn superoxide dismutase 1
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14: 744.2 ± 323.8 cells/mm2, n = 5; BMMC injected in
week 14: 824.5 ± 333.7 cells/mm2, n = 6).
Fate of BMMC after spinal cord injection
In this study, we used different techniques in order to in-
vestigate the fate of the injected cells. In the first approach,
we used cells from transgenic mice carrying the enhanced
green fluorescent protein (eGFP) under the control of the
actin promoter. The fate of BMMC-eGFP transplanted in
presymptomatic animals was analyzed at 4, 7, and 65 (end
stage) days after the injection. In sections of spinal cord
tissue we observed many eGFP cells 4 days after the injec-
tion, distributed on the dorsal–ventral axis. However, the
number of these cells decreased drastically by 7 days, and
at the end stage we could not find any transplanted cells
(Fig. 5). Analyzing the distribution of microglia (Iba1-posi-
tive cells) in the same animals, we observed that 4 days
after injection many BMMC were found in association
with microglia (Fig. 5a, arrows). Seven days after injection,
the few BMMC observed were not clearly associated with
microglia (Fig. 5b′).
Alternatively, we also labeled the cells with the fluores-
cent marker CellTrace™ before injection. Seven days after
injection of BMMC in a symptomatic animal, it was pos-
sible to observe CellTrace™-labeled cells in the spinal cord
sections. However, we did not observe the usual cytoplas-
matic pattern of labeling, and only a few cells showed the
staining associated with cell nuclei (Fig. 6). Analyzing
microglia in these animals, we observed a high concentra-
tion of microglia in the injection site (square in Fig. 6a
and at higher magnification in Fig. 6b–d), where many
cells exhibited a round phagocyte morphology similar to
the transplanted cells (Fig. 6b–d, arrows).
To further investigate the fate of the transplanted
cells, we labeled them with SPION prior to the injec-
tion and we imaged the spinal cord region in vivo with
MRI for several weeks in the same animal. We were
able to detect the injected cells as a hypointense signal
in the spinal cord, and this signal was present at all
stages examined (Fig. 7, arrows). Importantly, even
72 days after the injection (end stage of the animal
injected in week 9) the signal was still present at the
injection site. Histological analyses of these animals
were performed in order to identify whether the signal
could be correlated with cell bodies or was due to free
iron. We used differential and interferential contrast
to observe the SPION and Iba1 to identify microglia/
macrophages. The majority of the SPION staining was
located in the ventral horn, and most of the iron
seemed be associated with Iba1-positive cells (Fig. 7,
arrowheads). However, it was possible to find some
SPION that was not associated with the Iba1 staining
(Fig. 7, arrows).
Discussion
ALS is a fatal neurodegenerative disease for which there
is no available treatment, and patients survive only 3–5
years on average after the symptoms start. ALS is a
multifactorial disease, and different cell types seem to
play important roles in the physiopathology. The need
for an effective treatment has stimulated many re-
searchers to test cell therapy. In our study, we injected
BMMC into a mouse ALS model during the presymp-
tomatic and symptomatic phases of the disease, to test
its therapeutic potential.
Bone marrow cell therapy seems to be a promising treat-
ment for ALS. This approach has shown good results in
preclinical studies of other neurological diseases or traumas
in the CNS, such as brain ischemia or optic-nerve crush
[17, 25, 28]. The BMMC fraction constitutes a heteroge-
neous population formed mainly by hematopoietic cells,
such as monocytes, lymphocytes, and granulocytes, and a
small percentage of mesenchymal and hematopoietic stem
cells, as described previously by our group [19]. BMMC
treatment has proven to increase nerve regeneration and
neural stem cell proliferation, and to reduce neuronal death
and microglia activation [17, 19, 26, 29]. The main mechan-
ism attributed to these beneficial effects is the capacity to
release growth factors and cytokines [30, 31]. Besides this,
the ALS model demonstrated that both wild-type
monocytes and T lymphocytes (both cell types present
in BMMC) delay disease progression in the mouse
model, and could contribute to the beneficial effect of
this therapy [4, 12].
BMMC therapy has already been tested in clinical tri-
als for different neurological diseases [32, 33]. In ALS
patients there is a clinical trial injecting these cells into
the spinal cord, demonstrating that this approach is
feasible and safe [23]. However, it is also important to
analyze the efficacy of this therapy. Preclinical studies,
as the present one, could contribute to the design of
phase 2/3 clinical trials to test efficacy, such as through
analysis of the best time points, dose, and routes of
administration.
In this work, we performed different functional tests
and histopathological analyses of the SOD1G93A ani-
mals treated with BMMC in two distinctive time points.
In order to analyze the functional deficit, we use three
distinctive tests—rotarod, hanging wire, and motor
score. Comparing the gender-matched SOD1G93A ani-
mals’ performance in these tests with the wild-type ani-
mals’ performance, we could observe when the deficits
start in our animals and we were able to observe a
delay in the beginning of the motor loss in the BMMC-
treated animals in the presymptomatic phase of the dis-
ease—although we were not able to see significant
differences when we compared untreated and treated
SOD1G93A groups. Treatment in the symptomatic phase
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had no effect. Neither therapy had an effect on sur-
vival. These results are different from most of the
studies that have used bone marrow cells in rodent
ALS models. Nevertheless, there are important differ-
ences between our study and others that have been
reported.
In mouse ALS models, wild-type bone marrow cells were
used to replace the bone marrow from irradiated
SOD1G93A animals. The cells were transplanted in the pre-
symptomatic phase, migrated, and invaded the spinal cord
during the course of the disease. Under this approach, the
results were contradictory: one group observed an increase
Fig. 5 Fate tracing of BMMC-injected cells. BMMC expressing eGFP under the actin promoter were transplanted into the spinal cord of SOD1G93A
mice in week 9 a, b. a Photomontage of confocal images showing a transverse section of lumbar spinal cord 4 days after BMMC transplant. Observe the
wide distribution of BMMC-eGFP+ (green) on the dorsal–ventral axis. White boxes in a show in higher magnification (a′, a″) the association of BMMC with
microglia stained with Iba1 (red). Arrows (a′, a″) indicate transplanted cells associated with microglia. b Photomontage of confocal images showing a
transverse section of lumbar spinal cord 7 days after BMMC transplant. There was a sharp decrease in the number of BMMC-eGFP+ in the spinal cord.
Some of the few remaining cells were not clearly associated with microglia (arrowheads in b′). Arrows (b″) indicate one of the few transplanted cells
associated with microglia. b′, b″ show a higher magnification of white boxes in b. Scale bar: 50 μm. d.a.i. days after injection, D dorsal, M medial
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in lifespan, while another found no positive effect [34, 35].
These conflicting results could be due to the number of
cells that reached the damaged area. In our study, we
injected BMMC directly into the lumbar spinal cord of
presymptomatic SOD1G93A mice, and we observed a posi-
tive result only in the functional outcome but not in the
lifespan. However, since we performed a single local injec-
tion and we did not observe migration of these cells out-
side the injection site, it is possible that multiple injections
are required to observe a more substantial positive effect in
the functional outcome and survival. To our knowledge,
this is the first report that injects BMMC into the spinal
cord of SOD1G93A mice.
The number of injected cells could also be crucial to
obtain a positive outcome. Previous works using 105
mesenchymal stem cells or 2 × 104 neural stem cells
observed an increase in the lifespan of ALS mice [20, 36].
Pastor et al. [37] injected 106 bone marrow cells into
the spinal cord parenchyma of mdf/ocd mice, and ob-
served a beneficial functional effect. However, in the
present work, using the same amount of BMMC in the
SOD1G93A mice model, we only saw a slight positive
effect in the presymptomatic injected animals. One
possible explanation is that although we injected a sig-
nificant amount of cells, BMMC do not seem to persist
in the spinal cord for a long period.
It is possible that the injection into the spinal cord
could stimulate more inflammation, worsening the situ-
ation and leading to a decrease in the survival time.
However, we also did not see a decrease in survival
comparing the saline-injected animals with SOD1G93A mice
that did not undergo any procedure (Additional file 2:
Fig. 6 Fate tracing of BMMC-injected cells stained with CellTrace™. BMMC stained with the fluorescent cell marker CellTrace™ (green) were transplanted
into the spinal cord of SOD1G93A mice in week 14. Photomontage of confocal images showing a transverse section of lumbar spinal cord 7 days after
BMMC transplant. We observed a dispersed pattern of CellTrace™ staining in the ventral horn. Microglia were stained with Iba1 (red). Observe the high
concentration of microglia at the injection site (white box in a). b–d Higher magnification of the area delimited by the white box in a, showing the
association of BMMC with microglia stained with Iba1. Arrows in b–d indicate microglia phagocyte profiles interacting with the transplanted cells. Scale
bar: 50 μm
Gubert et al. Stem Cell Research & Therapy  (2016) 7:41 Page 10 of 14
Figure S2). Moreover, considering that other groups have
previously tested this approach, as already described, the
strategy of injecting cells directly into the spinal cord seems
to be feasible.
We observed an increase in survival in the animals
treated in week 14 when compared with noninjected
mice. However, we did not observe this difference be-
tween saline and treated mice in week 14. It is important
to highlight that most of saline-injected and BMMC-
injected mice in week 14 were littermates, which de-
creases possible variability. We also observed that only
in the BMMC-treated mice in the symptomatic phase
did a couple of animals survive more than 160 days.
Thus, it is possible that by increasing the number of cells
or the number of injection sites we would observe a
positive effect of the therapy.
Fig. 7 In vivo fate tracing of BMMC-injected cells. BMMC were labeled with SPION and injected into the lumbar spinal cord in week 9 a–c or in
week 14 d–f. Representative images of in vivo MRI in longitudinal planes of the spinal cord at different time points. Arrows indicate hypointense
(black) areas corresponding to SPION-labeled cells in the spinal cord. Labeled cells were found at day 1 a, d, day 8 b, e, and at the end stage of
the disease, which corresponds to 72 days after presymptomatic injection c and 34 days after symptomatic injection f. g Transverse section of
the spinal cord from the animal analyzed by MRI in f. SPION staining is revealed by differential and interference contrast (dark signal in g–i). Iba1
was used to identify microglia/macrophages (red). We observed only faint staining throughout the spinal cord, with most of the SPION staining located
in the ventral horn. Some SPION staining was associated with Iba1-positive cells (arrowheads in i) and some with Iba1-negative cells (arrows in i). Scale
bar: 50 μm
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In this work, we analyzed whether BMMC therapy
could affect differently male and females. It is well known
that in this animal model females show a longer lifespan
than males [38]. This difference could be the result of a
protective role of estrogen [39]. In our study, we observe a
discrete influence of gender in the functional tests. In the
presymptomatic injection, the therapy seems to be more
effective in females than males, since BMMC-treated fe-
male mice showed a delay in functional loss in all tests
performed, while treated males showed this only in the
hanging-wire test. In the symptomatic injection, when we
separate the groups by gender, we were able to see an im-
provement or stabilization in the functional outcome, es-
pecially in males for the rotarod test. Others studies had
demonstrated a distinguished response by gender in many
therapies. For instance, Kondo et al. [40] demonstrated
that lumbar-injected glial-rich neural progenitors im-
proved survival only in males. Morita et al. [41], however,
showed that intrathecal transplanted mesenchymal stem
cells decrease disease duration only in females. So far,
there is still no solid explanation for how distinguished
therapies could act differently in males and females.
In this study, we tried different techniques in order to
trace the fate of the injected cells. Using MRI, we could
observe the BMMC injected in the same animal during
the course of the disease. Until the end stage, these cells
seemed to remain close to the site of injection. This low
migration rate could be the reason why we observed an
effect only in the functional test, but not in the life-
span, since the neurodegeneration occurs in the entire
spinal cord, not only in the lumbar region. In order to
overcome this possible problem, it could be interesting
to test multiple injections into different regions of the
spinal cord.
Importantly, we could only observe BMMC until the
end stage of the disease by using SPION labeling. When
we injected eGFP-BMMC or BMMC labeled with Cell-
Trace™, we could not track the cells until the end stage.
A possible explanation is that the fluorescent stain is less
stable, and during the procedures to analyze the spinal
cord this stain was lost. However, when we used a spe-
cific antibody against eGFP, we still could not find the
cells. When we analyzed the BMMC labeled with SPION
in cryosections of the spinal cord, we could see that
many labeled cells were in close apposition to Iba1-
positive cells. It could be argued that most of the BMMC
were phagocytized by resident microglia, and these cells
retained the SPION label. However, the BMMC popula-
tion includes monocytes, which could survive in the
spinal cord and differentiate into macrophages that also
express Iba1. Nevertheless, we also found SPION-
labeled cells that did not stain with Iba1, suggesting
that at least a part of the BMMC population was not
phagocytized.
Many groups have tried different drugs to reduce the
disease progression and extend the lifespan in animal
ALS models. However, although some of them showed
positive effects in the animal test, the results did not
translate to clinical practice [42]. One of the main con-
cerns at present is that most of the preclinical studies
treat the animals in the presymptomatic phase. In this
period, the animals do not show functional deficits or
significant motor neuronal death. This contrasts with
the clinical trials, where the patients already show sig-
nificant loss of function. In this study we injected
BMMC at two different time points, in the presymptom-
atic phase (9 weeks old) and in the symptomatic phase
(14 weeks old). We observed a positive effect in the
functional tests when we injected the BMMC in the
presymptomatic phase, but not in the symptomatic
phase. It is possible that the environment in the symp-
tomatic phase is already too damaged to recover with
this therapy, and it is important to take this into con-
sideration before attempting to translate this treatment
to human patients.
Conclusion
The results presented here demonstrate that BMMC
therapy, used in the presymptomatic phase, could retard
the loss of function in SOD1G93A mice. An increase in
the number of injection sites could improve this out-
come. However, when BMMC were injected in the
symptomatic phase we could not see any effect; this
indicates that we should look for another type of cell or
even combine pharmacological therapy with cell therapy
to potentiate the results in the symptomatic phase.
Additional files
Additional file 1: Figure S1. Quantification of neurons in the anterior
horn of the spinal cord. The number of interneurons (NeuN-positive
cells with cross-sectional area ≤250 μm2) was analyzed in week 12 in the
presymptomatic injected animals a and in week 15 in the symptomatic
injected animals b. There was no difference in the number of interneurons
in the SOD1G93A mice compared with the wild-type animals. The number of
motor neurons was analyzed in the end stage of the disease in the
presymptomatic injected animals c and in the symptomatic injected animals
d. Both saline-injected and BMMC-injected mice showed a decrease in the
number of motor neurons compared with the wild-type mice at the time
point analyzed. ***p <0.001. (TIF 745 kb)
Additional file 2: Figure S2. Survival do SOD-1G93A mice. a, b
Comparison of survival of SOD-1G93A mice that did not suffer any surgical
procedure with SOD-1G93A mice injected with saline at two different time
points: presymptomatic phase (9 weeks old) and symptomatic phase (14 weeks
old). No differences were observed between the groups. (TIF 288 kb)
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